Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.
Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]
The market for biosimilars is funky The industry thinks PBMs are to blame washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.